SCHEMBL342763

SCHEMBL342763

CC(C)(C)OC(=O)N1C[C@H](C(=O)O)C[C@H](C2CCCCC2)C1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR1H2 P55055 1/20 0.55
HPGD P15428 1/20 0.47
EPHX1 P07099 1/20 0.45
HSD17B10 Q99714 1/20 0.44
MEN1 O00255 1/20 0.43
ALDH1A1 P00352 1/20 0.43
MAPT P10636 1/20 0.43
KMT2A Q03164 1/20 0.43
GPR119 Q8TDV5 3/20 0.42
JAK2 O60674 1/20 0.41
JAK1 P23458 1/20 0.41
BTK Q06187 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.39
HSD11B1 P28845 1/20 0.39
RECQL P46063 1/20 0.39
PDE4B Q07343 1/20 0.39
PREP P48147 2/20 0.39
CHRM2 P08172 1/20 0.38
CHRM1 P11229 1/20 0.38
CHRM3 P20309 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL342765 1.00 NR1H2 (0.55) NR1H2HPGDEPHX1HSD17B10MEN1
SCHEMBL342764 1.00 NR1H2 (0.55) NR1H2HPGDEPHX1HSD17B10MEN1
SCHEMBL31045773 0.94 NR1H2 (0.57) NR1H2HPGDEPHX1HSD17B10MEN1
SCHEMBL2978266 0.88 NR1H2 (0.64) NR1H2HPGDHSD17B10MEN1ALDH1A1
SCHEMBL16962257 0.88 NR1H2 (0.64) NR1H2HPGDHSD17B10MEN1ALDH1A1
SCHEMBL28688547 0.88 NR1H2 (0.64) NR1H2HPGDHSD17B10MEN1ALDH1A1
SCHEMBL16042198 0.88 NR1H2 (0.64) NR1H2HPGDHSD17B10MEN1ALDH1A1
SCHEMBL28914482 0.88 NR1H2 (0.64) NR1H2HPGDHSD17B10MEN1ALDH1A1
SCHEMBL22629774 0.88 NR1H2 (0.64) NR1H2HPGDHSD17B10MEN1ALDH1A1
Hydrochloric Acid SCHEMBL2977900 0.86 NR1H2 (0.62) NR1H2HPGDHSD17B10MEN1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8367690-B2 Aminopyridine derivatives having aurora a selective inhibitory action VERTEX PHARMACEUTICALS INC. (US) 2013-02-05 US disclosed
US-8367690-B2 Aminopyridine derivatives having aurora a selective inhibitory action VERTEX PHARMACEUTICALS INC. (US) 2013-02-05 US disclosed
US-20120015969-A1 NOVEL AMINOPYRIDINE DERIVATIVES HAVING AURORA A SELECTIVE INHIBITORY ACTION BANYU PHARMACEUTICALS CO., LTD. (JP) 2012-01-19 US disclosed
US-20120015969-A1 NOVEL AMINOPYRIDINE DERIVATIVES HAVING AURORA A SELECTIVE INHIBITORY ACTION BANYU PHARMACEUTICALS CO., LTD. (JP) 2012-01-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120015969-A1 NOVEL AMINOPYRIDINE DERIVATIVES HAVING AURORA A SELECTIVE INHIBITORY ACTION AURKA, AURKC, AURKB NR1H2 3181/4885HPGD 4089/4885EPHX1 3138/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.